Catabasis Announces Proposed Underwritten Public Offering

- January 30th, 2020

Catabasis announced that it intends to offer its securities in an underwritten public offering, subject to market and other conditions.

Catabasis Pharmaceuticals (NASDAQ:CATB) announced that it intends to offer its securities in an underwritten public offering, subject to market and other conditions.

As quoted in the press release:

Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.

Catabasis intends to use the net proceeds from the offering for clinical trial and other research and development activities; initial commercialization preparations; and for working capital and other general corporate purposes.

The securities described above will be offered pursuant to a shelf registration statement on Form S-3 (No. 333-231441), which was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”) on May 23, 2019.

Click here to read the full press release.

We found the top performing pharma stocks to watch this year

Find out more in our report
 

Leave a Reply